Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Planet Labs (PL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Planet Labs — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Planet Labs trades at $13.72 (market cap $5.52B). The key difference: Planet Labs is far larger — about 5.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Planet Labs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Planet Labs for 6 Days on average.
| MRVI | PL | |
|---|---|---|
Market Cap | $972.90M | $5.52B |
Volume | 4,325,710 | 10,123,547 |
Sector | Health | Industrials |
52-Week High | $9.00 | $51.40 |
52-Week Low | $2.83 | $11.16 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Planet Labs (PL) trades at $15.16, down 5.01% on the day, reflecting ongoing bearish technical pressure despite recent satellite launches and government contract wins. The company shows revenue growth potential with $378 million projected for 2026, but faces significant profitability challenges with a -95.13% net income margin and negative ROE of -71.97%. Analyst sentiment remains positive with 13 buy ratings and a $32.50 consensus price target, though technical indicators signal bearish momentum.
The stock presents a high-risk opportunity with substantial upside potential if execution improves, but current financial performance and bearish technicals warrant caution. Key catalysts include defense contract execution and satellite deployment success, while risks include persistent losses, competitive pressure from SpaceX, and valuation concerns at current P/S of 13.35.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Planet Labs
Planet Labs operates Earth-imaging satellites and provides geospatial data products. Its imagery and analytics help governments and businesses monitor changes across the planet.
Read more on PL →
